Harnessing the Unique Features of Macrophage Therapies with CAR Technology (CAR-M) to Fight Solid Tumors

Time: 4:00 pm
day: Day 1 - Track B - Post Lunch


  • Maintaining the anti-tumoral polarization within the TME and selective targeting of cancer cells by direct killing activity
  • Phagocytosis of tumor target leads to cross-presentation of tumor antigen and activation of an adaptive immune response
  • Presenting initial data from CT-0508 phase I clinical study, studying the impact of Her2-directed CAR-M in solid tumor